Neumora Therapeutics, Inc. Common Stock
NASDAQ: NMRA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daljit Singh Aurora
- Employees
- 110
- Headquarters
- Watertown, United States
- IPO year
- 2023
- Market cap
- $270.5M
- Website
- https://www.neumoratx.com
Loading NMRA…
Loading profile data…Frequently asked questions about NMRA
What does Neumora Therapeutics, Inc. Common Stock (NMRA) do?
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist cur...
Where does NMRA trade?
Neumora Therapeutics, Inc. Common Stock (NMRA) trades on the NASDAQ Global Select.
What sector is NMRA in?
Neumora Therapeutics, Inc. Common Stock (NMRA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Neumora Therapeutics, Inc. Common Stock?
Daljit Singh Aurora is the chief executive officer of Neumora Therapeutics, Inc. Common Stock (NMRA).
Where is Neumora Therapeutics, Inc. Common Stock headquartered?
Neumora Therapeutics, Inc. Common Stock is headquartered in United States.
Does NMRA pay a dividend?
Neumora Therapeutics, Inc. Common Stock (NMRA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NMRA go public?
Neumora Therapeutics, Inc. Common Stock (NMRA) completed its initial public offering in 2023.